5-({[tert-butyl(dimethyl)silyl]oxy}methyl)pyridine-2-arboxaldehyde | 212914-72-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-({[tert-butyl(dimethyl)silyl]oxy}methyl)pyridine-2-arboxaldehyde
• 英文别名: 5-[[[tert-butyl(dimethyl)silyl]oxy]methyl]-2-pyridine-carbaldehyde；5-[[[tert-butyl(dimethyl)silyl]oxy]methyl]-2-pyridinecarbaldehyde；5-({[tert-butyl(dimethyl)silyl]oxy}methyl)pyridine-2-carbaldehyde；5-(t-butyldimethylsilyloxymethyl)pyridine-2-carbaldehyde；2-Pyridinecarboxaldehyde, 5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-；5-[[tert-butyl(dimethyl)silyl]oxymethyl]pyridine-2-carbaldehyde
• CAS: 212914-72-2
• 化学式: C₁₃H₂₁NO₂Si
• 分子量: 251.401
• InChiKey: HLUNPSZBWDNDTR-UHFFFAOYSA-N

物化性质

• 沸点：
  318.1±27.0 °C(Predicted)
• 密度：
  0.998±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.42
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-({[tert-butyl(dimethyl)silyl]oxy}methyl)pyridine-2-arboxaldehyde 在 乙酸铵 、 manganese(IV) oxide 、 ammonium hydroxide 、 正丁基锂 、 盐酸羟胺 、 三乙胺 、 锌 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 氯仿 为溶剂， 反应 23.67h， 生成 bis[5-[[[tert-butyl(dimethyl)silyl]oxy]methyl]-2-pyridinyl]methylamine
  参考文献：
  名称：

  Synthesis of a Non-Heme Template for Attaching Four Peptides:  An Approach to Artificial Iron(II)-Containing Peroxidases

  摘要：

  We are developing all-synthetic model cofactor-protein complexes in order to define the parameters controlling non-natural cofactor activity. The long-term objective is to establish the theoretical and practical basis for designing novel enzymes. A non-heme pentadentate ligand (N4Py) is being developed as a template for the site-specific attachment of a designed four-helix bundle. Previously, we attached two unprotected peptides via CH2Cl handles to N4Py. In the presence of hydrogen peroxide, the iron(II) complex of this ligand (2a) generates an (FeOOH)-O-III intermediate (3a) that can oxidize a wide variety of organic compounds. Here, we describe the synthesis of 27, a N4Py derivative in which four three-carbon spacers have been introduced, and show that four copies of an unprotected, single-cysteine peptide can be coupled via a thioether linkage to the ligand. In addition, a divergent synthesis route to tetrabromide ligand 1b has also been developed, providing the opportunity to prepare alternative pentadentate ligands efficiently by four cross-coupling reactions on a single molecule. Also, two of the four bromides of 1b can be selectively addressed by magnesium-bromide exchange.

  DOI：

  10.1021/jo035157z
• 作为产物：
  描述：

  2-溴-5-醛基吡啶 在 sodium tetrahydroborate 、 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 生成 5-({[tert-butyl(dimethyl)silyl]oxy}methyl)pyridine-2-arboxaldehyde
  参考文献：
  名称：

  Synthesis of a Non-Heme Template for Attaching Four Peptides:  An Approach to Artificial Iron(II)-Containing Peroxidases

  摘要：

  We are developing all-synthetic model cofactor-protein complexes in order to define the parameters controlling non-natural cofactor activity. The long-term objective is to establish the theoretical and practical basis for designing novel enzymes. A non-heme pentadentate ligand (N4Py) is being developed as a template for the site-specific attachment of a designed four-helix bundle. Previously, we attached two unprotected peptides via CH2Cl handles to N4Py. In the presence of hydrogen peroxide, the iron(II) complex of this ligand (2a) generates an (FeOOH)-O-III intermediate (3a) that can oxidize a wide variety of organic compounds. Here, we describe the synthesis of 27, a N4Py derivative in which four three-carbon spacers have been introduced, and show that four copies of an unprotected, single-cysteine peptide can be coupled via a thioether linkage to the ligand. In addition, a divergent synthesis route to tetrabromide ligand 1b has also been developed, providing the opportunity to prepare alternative pentadentate ligands efficiently by four cross-coupling reactions on a single molecule. Also, two of the four bromides of 1b can be selectively addressed by magnesium-bromide exchange.

  DOI：

  10.1021/jo035157z

文献信息

• DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：EP2272841A1

  公开（公告）日：2011-01-12

  [Problem] To provide a melanin-concentrating hormone receptor antagonist useful as a pharmaceutical agent for central diseases, circulatory diseases, and metabolic diseases. [Means for Resolution] Provided is a diarylmethylamide derivative represented by formula (I): Wherein R1a, R1b, R2a, R2b, R3a, and R3b independently represent a hydrogen atom or the like, R4 represents a hydrogen atom, C1-6 alkyl, or the like, R5 represents a hydrogen atom or the like, Z represents C1-6 alkyl or the like, or R4 and Z together form a 4- to 6-membered nitrogen-containing hetero ring, Y1 represents H or the like, Y2 represents H, or Y1 and Y2 together form - O-CH2-, W represents C, SO, or the like, Ar1 represents 6-membered aryl or the like, Ar2 represents 6-membered aryl or the like, and ring A represents a benzene ring, a pyridine ring, or the like.

  [问题] 提供一种对黑色素浓缩激素受体拮抗剂，用作中枢疾病、循环疾病和代谢疾病的药用制剂。 [解决方法] 提供一种由式(I)表示的二芳基甲酰胺衍生物： 其中R1a、R1b、R2a、R2b、R3a和R3b独立地表示氢原子或类似物，R4表示氢原子、C1-6烷基或类似物，R5表示氢原子或类似物，Z表示C1-6烷基或类似物，或者R4和Z一起形成一个含氮杂环的4-至6-成员环，Y1表示H或类似物，Y2表示H，或者Y1和Y2一起形成-O-CH2-，W表示C、SO或类似物，Ar1表示6-成员芳基或类似物，Ar2表示6-成员芳基或类似物，环A表示苯环、吡啶环或类似物。
• Indolopyrrolocarbazole derivatives and antitumor agents
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US06703373B1

  公开（公告）日：2004-03-09

  A compound represented by the formula or a pharmaceutically acceptable salt thereof wherein R represents an unsubstituted pyridyl, furyl or thienyl group, or a pyridyl, furyl or thienyl group each of which has one or more substituents selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group except that when the pyridyl, furyl or thienyl group has a lower alkoxy group as a substituent, each of which simultaneously has another substituent selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group, m represents an integer of 1 to 3, and G represents a &bgr;-D-glucopyranosyl group, and the positions of substitution of the hydroxyl groups on the indolopyrrolocarbazole ring are the 1- and 11-positions, or the 2- and 10-positions, and an antitumore agent containing it as an effective ingredient. The compounds have a better antitumor action than known compounds having a similar structure.

  化合物的化学式为或其药学上可接受的盐，其中R代表未取代的吡啶基，呋喃基或噻吩基，或者是带有一个或多个取代基的吡啶基，呋喃基或噻吩基，所述取代基选自羟基，较低的烷氧基，羟基较低的烷基基团和羟基较低的烯基基团的群，但是当吡啶基，呋喃基或噻吩基带有较低的烷氧基取代基时，每个取代基同时具有羟基，较低的烷氧基，羟基较低的烷基基团和羟基较低的烯基基团中的另一个取代基时，m表示1到3的整数，G表示β-D-葡萄糖吡喃糖基，并且羟基取代在吲哚吡咯喹啉环上的位置为1-和11-位置，或2-和10-位置，以及含有其作为有效成分的抗肿瘤剂。这些化合物比具有类似结构的已知化合物具有更好的抗肿瘤作用。
• VOLTAGE-GATED SODIUM CHANNEL BLOCKERS
  申请人：Boehm Jeffrey Charles

  公开号：US20130023541A1

  公开（公告）日：2013-01-24

  The present invention relates to voltage-gated sodium channel blocker intermediates, compounds and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory or respiratory tract diseases.

  本发明涉及电压门控钠通道阻滞剂中间体、化合物和二聚体，相应的药物组合物、化合物制备和治疗呼吸或呼吸道疾病的方法。
• [EN] IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF<br/>[FR] COMPOSÉ IMIDAZOLE ET INTERMÉDIAIRE ET LEUR UTILISATION<br/>[ZH] 一种咪唑类化合物、其中间体及应用
  申请人：[en]ZHUGE, Guoqin;[zh]诸葛国琴

  公开号：WO2023274257A1

  公开（公告）日：2023-01-05

  一种如式I所示的咪唑类化合物或其药学上可接受的盐以及中间体，该如式I所示的咪唑类化合物能够显著抑制AA诱导的血小板聚集，改善MCAO/R所致大鼠脑缺血损伤，代谢稳定性优异，能够提高药物在脑组织分布，从而增强其治疗急性血栓性脑梗死和脑梗死所伴随的运动障碍药效活性。
• Enantioselective ethylation of aldehydes using a regenerable polymer-supported N-picolylvalinol tridentate ligand
  作者：Vinciane Kelsen、Philippe Pierrat、Philippe C. Gros

  DOI：10.1016/j.tet.2007.07.077

  日期：2007.10

  A supported pyridine-based tridentate chiral ligand has been prepared and evaluated for enantioselective addition of diethylzinc to aldehydes. The catalyst allowed the preparation of various chiral alcohols with the R configuration in good yields and enantiomeric excesses (up to 93%) and was found reusable. (C) 2007 Elsevier Ltd. All rights reserved.